-+ 0.00%
-+ 0.00%
-+ 0.00%
Zealand Pharma Launches Phase 2 Dose-finding Trial for Obesity Treatment Combo
Share
Listen to the news
01:28 AM EST, 11/18/2026 (MT Newswires) -- Zealand Pharma (ZEAL.CO) initiated the phase 2 trial to evaluate the efficacy and safety of petrelintide when administered with enicepatide in obesity patients who have at least one weight-related comorbidity. The biotechnology company said Wednesday that the Zynergy dose-finding trial is expected to consist of 480 patients, with Roche (RO.SW) sponsoring and conducting the over-40-week study. The primary endpoint will focus on the body weight percentage change over the course of the trial, with the waist circumference and hemoglobin A1c changes being secondary endpoints.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending